Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval this week as a first-line treatment for ...

It's unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is ...

Ericsson joining Avanci Video as a licensor and the EUIPO's plans for AI use were also among the top talking points this week ...

Cipla rallied 3.80% to Rs 1,470.15 after the firm received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Paclitaxel, a generic ...

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

Elara had already factored in approximately $20 million in revenue from gAbraxane in the US for FY26. While 3–4 generic ...